SeaLink Capital Partners

Heramb Hajarnavis is the Founder and Managing Partner, supported by Partners Karthik Narayanaswamy and Rahul Sanghavi. The firm lists all three investment professionals on its public website, suggesting a lean, consensus-driven investment committee structure rather than a hierarchical model.

SCP sources through direct founder relationships and deep sector networks in Indian healthcare and technology, with a stated preference for entrepreneurs who have high integrity standards. Testimonials from portfolio company leaders indicate the firm builds relationships over extended pre-investment periods, and its active post-investment board involvement generates referral flow from existing founders and industry executives.

SCP is structured as a direct investment firm focused on growth-stage equity deals in mid-sized Indian enterprises. The firm does not publicly operate a fund-of-funds program or make LP commitments to external managers. Its capital deployment appears concentrated in direct, control-oriented minority stakes.

SCP targets growth-stage companies with strong competitive differentiation and proven business models, not seed or early-stage startups. The firm's known investments — Surya Hospitals, Global Dental Services, THB, Ki Mobility, and the prior NephroPlus position — are all established operating businesses with material revenue and market presence at the time of investment.

SCP states it focuses on select sectors, and its disclosed portfolio reveals a tight concentration in healthcare services (hospitals, dental, dialysis, healthcare analytics) and tech-enabled business services (automotive aftermarket SaaS). The firm has no publicly known investments in consumer internet, fintech, hard infrastructure, or heavy manufacturing, suggesting a deliberate exclusion of sectors outside its core operational expertise.

SCP's model is unusual for a growth-equity firm: it embeds partners into board governance and actively drives operational initiatives. At NephroPlus, SCP led work on employee compensation structures, ESOP allocation, pricing strategy, pharmacy revenue improvements, and inorganic acquisitions. At Surya Hospitals, founder Dr. B.S. Avasthi noted the firm is "very actively involved in our operations" and that "debates and discussions" helped improve hospital performance — a level of engagement more typical of control buyout firms than minority growth investors.

SCP does not publicly disclose any philanthropic foundation, impact vehicle, or charitable structure. The firm's website and portfolio-company testimonials focus exclusively on for-profit growth investing, with no indication of a parallel philanthropic mandate or program-related investment pool.